Published
June 20, 2026
If you bought QVAR or QVAR RediHaler asthma inhalers since 2015, you can file for a cash payment from Teva's $35 million settlement — proof of purchase is required for consumer claims.
What Is the QVAR Antitrust Settlement About?
Teva has agreed to a $35 million class action settlement to resolve antitrust claims over its QVAR and QVAR RediHaler asthma inhalers. The end-payor lawsuit alleges that Teva used a combination of product reformulations, strategic patent listings in the FDA's Orange Book, and related litigation to block or delay lower-cost generic versions of QVAR from reaching the market. When generics are kept off the market, consumers and insurers have no cheaper alternative and end up paying brand-name prices longer than they otherwise would. Teva denies the allegations and is settling without admitting any wrongdoing or liability.The case is captioned Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., No. 1:23-cv-11131-NMG, and is pending in the U.S. District Court for the District of Massachusetts before Judge Nathaniel M. Gorton. The court granted preliminary approval in April 2026, the official settlement website is live, and the claim deadline is July 31, 2026. For the latest case-status and procedural updates, see our QVAR settlement news update.
Status
Claims Open
claim form is live · preliminary approval granted April 2, 2026
Claim Deadline
July 31, 2026
final approval hearing set for August 5, 2026
Settlement Fund
$35 Million
pro rata cash · plus Teva's reported agreement to withdraw certain QVAR patents from the FDA Orange Book
Proof Required
Yes
proof of purchase is required for consumer claims — you can submit the form first, but the administrator will request records (pharmacy/insurer records, EOBs, prescription history, receipts), and claims without adequate documentation may be audited, reduced, or rejected · third-party payors must submit transaction data
Who Qualifies for the QVAR Settlement?
You may qualify if you purchased, paid for, or were reimbursed for QVAR or QVAR RediHaler asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the eligible states. The settlement class covers two groups:• Individual consumers — people who bought QVAR out of pocket or through an insurance copay.
• Third-party payors — insurers, health plans, and other entities that paid for or reimbursed QVAR prescriptions for their members.
The class covers 41 states plus Washington, DC. The full list of eligible states is published in the official long-form notice on the settlement website. End-payor antitrust classes generally track the state laws that allow indirect purchasers to recover, so a handful of states without such laws are not included. If your state is not on the official list, you would not be part of this settlement class. Excluded from the class are the defendants and their affiliates, government entities, and class members who validly opt out.
How Much Can You Get?
Individual payout amounts have not been announced. The total settlement fund is $35 million. Class counsel has asked the court to approve up to roughly $11.5 million in attorneys' fees; if the court approves that request, the remainder forms the net fund before administration costs and other court-approved deductions.Payments are distributed pro rata, so each claimant's share depends on:
• The total number of valid claims filed.
• How much you spent on QVAR during the class period.
• How much purchase documentation you submit — proof of purchase is required for consumer claims, and better-documented claims receive a larger share.
Because the class spans roughly ten years and 41 states, individual amounts will vary widely. People who filled QVAR prescriptions frequently and over many years will generally receive more than someone who bought a single inhaler.
Do You Need Proof of Purchase?
Yes. Proof of purchase is required for consumer claims. You can submit the online claim form without attaching documentation, but the Claims Administrator will then request supporting records, and a claim without adequate documentation may be audited, reduced, or rejected. There is no administrator-issued Claim ID or PIN gating the form, so class members who never received a mailed or emailed notice can still start a claim — but they will need records to substantiate it. Accepted records include:• Pharmacy receipts or printouts showing the QVAR prescription and what you paid.
• Insurance Explanation of Benefits (EOB) statements listing QVAR prescription claims.
• Prescription history printouts from your pharmacy — most pharmacies will print or email a multi-year history on request.
• HSA or FSA statements showing QVAR purchases reimbursed through pre-tax accounts.
• A doctor's note or prescription records confirming a QVAR or QVAR RediHaler prescription.
• Receipts, credit-card statements, or checkbook entries showing a qualifying QVAR purchase.
Third-party payors file a separate claim and must substantiate their reimbursement data (typically through pharmacy claims records).
How to File a QVAR Settlement Claim
There are two ways to file, both with the same July 31, 2026 deadline.Method 1: Online. Visit the official settlement website at QVARAntitrustSettlement.com and complete the online claim form. Submit your proof of purchase — it is required for consumer claims, and the administrator will request records if you do not attach them up front.
Method 2: U.S. mail. Download the printable claim form from the settlement website, complete it, and mail it to the settlement administrator at the address listed on the form. Mailed claims must be postmarked no later than July 31, 2026.
The only official place to file is the settlement website. If you need a lost notice ID or a paper claim form, use the contact form on the official website rather than relying on any third-party "filing service."
Why the Orange Book Matters in This Case
The FDA's "Orange Book" is a federal database that lists patents tied to approved drugs. A generic applicant generally has to navigate around any Orange-Book-listed patent before the FDA will approve its version, so a brand-name manufacturer can use Orange Book listings to slow generic competition. The QVAR lawsuit alleges Teva listed patents that should not have been there and used them, along with product changes, to keep cheaper generic inhalers off the market. The Federal Trade Commission has previously scrutinized some of these same QVAR-related Orange Book listings.Beyond the $35 million cash fund, Teva reportedly agreed to withdraw certain QVAR-related patents from the Orange Book — a step that could make it easier for generic QVAR to reach the market in the future.
Key QVAR Settlement Deadlines
• Submit a claim by: July 31, 2026 (online or postmarked by mail).
• Class period covered: January 1, 2015 to July 31, 2025.
• Final Approval (fairness) hearing: August 5, 2026 at 2:00 p.m. ET, before Judge Nathaniel M. Gorton, U.S. District Court for the District of Massachusetts (Boston).
After final approval, if no appeals are filed, the administrator can begin distributing payments within a few months. Appeals can push distribution out by 12 to 36 months. The court-approved schedule and the exact opt-out and objection deadlines are posted on the official settlement website.
Watch Out for QVAR Settlement Scams
Newly launched settlement claim forms attract scammers. A few common-sense rules:• Never pay a fee. Legitimate class action settlements never require an activation, processing, or "release" fee to file a claim or receive a payment.
• Never share your full Social Security number, bank password, or card number with anyone claiming to handle your QVAR claim by phone, text, or email.
• Use the official website only: QVARAntitrustSettlement.com. Be cautious of any email or text linking to a "QVAR settlement" page from a different domain.
Other Pharmaceutical Antitrust Settlements
QVAR is one of several pharmaceutical antitrust and pay-for-delay cases moving through the courts. Being in one settlement does not affect your eligibility for any other unrelated case.• Tracleer (Bosentan) Pay-for-Delay Settlement — a $65 million end-payer settlement over alleged delayed generic competition for the pulmonary-hypertension drug Tracleer (third-party payors only).
• Teva, Granules & Heritage Metformin Settlement — a $5.55 million settlement covering U.S. buyers of certain recalled generic metformin (July 2015 – June 2020).
• OCA database of open class action settlements — the full list of active consumer cases you can still claim.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Claim Form Website: QVARAntitrustSettlement.com
File QVAR Claim — Official Site
Frequently Asked Questions About the QVAR Settlement
Who qualifies for the QVAR antitrust settlement?
Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR or QVAR RediHaler asthma inhalers between January 1, 2015 and July 31, 2025 in one of the 41 eligible states plus Washington, DC. The full state list is on the official settlement website.
What is the deadline to file a QVAR settlement claim?
July 31, 2026. Online claims must be submitted, and mailed claims postmarked, by that date. The final approval hearing is scheduled for August 5, 2026.
Do I need proof of purchase to file a QVAR claim?
Yes — proof of purchase is required for consumer claims. You can submit the form first, but the Claims Administrator will then request supporting records (pharmacy or insurer records, a doctor's note or prescription records, EOBs, receipts, credit-card statements, or checkbook entries), and a claim without adequate documentation may be audited, reduced, or rejected. There is no administrator-issued Claim ID or PIN required to file.
How much could each person get?
Individual amounts are not yet announced. The $35 million fund is distributed pro rata after attorneys' fees (requested at up to roughly $11.5 million), administration costs, and other court-approved deductions. Your share depends on the number of valid claims, how much you spent, and whether you submitted proof.
What did Teva allegedly do wrong with QVAR?
The lawsuit alleges Teva used product reformulations, strategic Orange Book patent listings, and related litigation to delay generic QVAR competition, keeping prices high. Teva denies wrongdoing and settled to avoid further litigation.
When will QVAR settlement payments be sent?
No confirmed date yet. After final approval (hearing set for August 5, 2026) and once any appeals are resolved, the administrator can begin distributing payments — typically within a few months if no appeals are filed; 12 to 36 months if there are appeals.
Sources
• Official Settlement Website: QVARAntitrustSettlement.com• Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., No. 1:23-cv-11131-NMG, U.S. District Court for the District of Massachusetts (Hon. Nathaniel M. Gorton)
• Reuters, "Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit" (October 2025)
• Long-Form Notice of Proposed Class Action Settlement and Settlement Claim Form
• FDA: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• FTC: Drug Pricing & Competition
Filing Class Action Settlement Claims
Please submit only truthful information on any claim. False or fraudulent claims can be rejected and may carry penalties. If you are not sure whether you qualify, review the eligibility information at QVARAntitrustSettlement.com. OpenClassActions.com is a consumer news site and is not the settlement administrator, class counsel, or a law firm, and we do not process or decide claims.
For more class actions keep scrolling below.
Settlement Amount
$35,000,000
Case Title
Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al.
Case Number
1:23-cv-11131-NMG
Court
U.S. District Court, District of Massachusetts
Final Approval Hearing
August 5, 2026 at 2:00 p.m. ET before Judge Nathaniel M. Gorton
Boston, Massachusetts
Administrator
A.B. Data, Ltd.
Official Website
QVAR Antitrust Settlement.com
